Do analysts recommend LFCR or AGFY?

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 47.73%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, equities analysts clearly believe Lifecore Biomedical is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifecore Biomedical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor LFCR or AGFY?

In the previous week, Lifecore Biomedical and Lifecore Biomedical both had 1 articles in the media. Agrify's average media sentiment score of 0.67 beat Lifecore Biomedical's score of 0.00 indicating that Agrify is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agrify 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AGFY or MENS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, AGFY or MENS?

Jyong Biotech has lower revenue, but higher earnings than Agrify. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agrify $12.26M 3.83 -$41.75M -$22.65 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is AGFY or MENS more profitable?

Jyong Biotech has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Jyong Biotech's return on equity of 0.00% beat Agrify's return on equity. Company Net Margins Return on Equity Return on Assets Agrify -424.11% -185.90% -72.67% Jyong Biotech N/A N/A N/A

Does the media prefer AGFY or MENS?

In the previous week, Agrify and Agrify both had 1 articles in the media. Jyong Biotech's average media sentiment score of 0.75 beat Agrify's score of 0.67 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agrify 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jyong Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AGFY or IMUX?

Immunic has a consensus target price of $47.25, suggesting a potential upside of 404.27%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Immunic 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, AGFY or IMUX?

Agrify has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agrify $12.26M 3.83 -$41.75M -$22.65 N/A Immunic N/A N/A -$97.17M -$4.38 N/A

Is AGFY or IMUX more profitable?

Immunic has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Immunic's return on equity of -157.89% beat Agrify's return on equity. Company Net Margins Return on Equity Return on Assets Agrify -424.11% -185.90% -72.67% Immunic N/A -157.89% -107.88%

Is NRXP or AGFY more profitable?

Agrify has a net margin of -424.11% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Agrify's return on equity. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals -691.81% N/A -63.92% Agrify -424.11% -185.90% -72.67%

Do analysts rate AGFY or UNCY?

Unicycive Therapeutics has a consensus price target of $18.75, indicating a potential upside of 289.81%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media prefer AGFY or UNCY?

In the previous week, Unicycive Therapeutics had 12 more articles in the media than Agrify. MarketBeat recorded 13 mentions for Unicycive Therapeutics and 1 mentions for Agrify. Agrify's average media sentiment score of 0.67 beat Unicycive Therapeutics' score of 0.04 indicating that Agrify is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agrify 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Agrify (AGFY) Competitors

$23.47 +0.19 (+0.82%)

As of 09/22/2026

Compare

AGFY vs. LFCR, MENS, IMUX, NRXP, and UNCY

Should you buy Agrify stock or one of its competitors? Agrify's main competitors and comparable companies include Lifecore Biomedical (LFCR), Jyong Biotech (MENS), Immunic (IMUX), NRx Pharmaceuticals (NRXP), and Unicycive Therapeutics (UNCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Agrify compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Lifecore Biomedical has higher revenue and earnings than Agrify. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.29	-$40.50M	-$1.07	N/A
Agrify	$12.26M	3.83	-$41.75M	-$22.65	N/A

Lifecore Biomedical has a net margin of -29.93% compared to Agrify's net margin of -424.11%. Lifecore Biomedical's return on equity of 0.00% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Agrify	-424.11%	-185.90%	-72.67%

Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Agrify has a beta of 9.96, indicating that its share price is 896% more volatile than the broader market.

In the previous week, Lifecore Biomedical and Lifecore Biomedical both had 1 articles in the media. Agrify's average media sentiment score of 0.67 beat Lifecore Biomedical's score of 0.00 indicating that Agrify is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agrify	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 47.73%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, equities analysts clearly believe Lifecore Biomedical is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 6.0% of Agrify shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 2.2% of Agrify shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lifecore Biomedical beats Agrify on 11 of the 15 factors compared between the two stocks.

How does Agrify compare to Jyong Biotech?

Agrify (NASDAQ:AGFY) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Agrify and Agrify both had 1 articles in the media. Jyong Biotech's average media sentiment score of 0.75 beat Agrify's score of 0.67 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agrify	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jyong Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.0% of Agrify shares are owned by institutional investors. 2.2% of Agrify shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Agrify has a beta of 9.96, meaning that its share price is 896% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, meaning that its share price is 124% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech has lower revenue, but higher earnings than Agrify.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.83	-$41.75M	-$22.65	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Jyong Biotech has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Jyong Biotech's return on equity of 0.00% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
Jyong Biotech	N/A	N/A	N/A

Summary

Jyong Biotech beats Agrify on 6 of the 10 factors compared between the two stocks.

How does Agrify compare to Immunic?

Agrify (NASDAQ:AGFY) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Immunic has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Immunic's return on equity of -157.89% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
Immunic	N/A	-157.89%	-107.88%

In the previous week, Agrify had 1 more articles in the media than Immunic. MarketBeat recorded 1 mentions for Agrify and 0 mentions for Immunic. Agrify's average media sentiment score of 0.67 beat Immunic's score of 0.00 indicating that Agrify is being referred to more favorably in the media.

Company	Overall Sentiment
Agrify	Positive
Immunic	Neutral

Agrify has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.83	-$41.75M	-$22.65	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

Agrify has a beta of 9.96, meaning that its share price is 896% more volatile than the broader market. Comparatively, Immunic has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

6.0% of Agrify shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 2.2% of Agrify shares are owned by company insiders. Comparatively, 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunic has a consensus target price of $47.25, suggesting a potential upside of 404.27%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Immunic beats Agrify on 9 of the 16 factors compared between the two stocks.

How does Agrify compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

NRx Pharmaceuticals has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market. Comparatively, Agrify has a beta of 9.96, meaning that its stock price is 896% more volatile than the broader market.

Agrify has a net margin of -424.11% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Agrify	-424.11%	-185.90%	-72.67%

In the previous week, Agrify had 1 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 1 mentions for Agrify and 0 mentions for NRx Pharmaceuticals. Agrify's average media sentiment score of 0.67 beat NRx Pharmaceuticals' score of 0.00 indicating that Agrify is being referred to more favorably in the news media.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
Agrify	Positive

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 6.0% of Agrify shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 2.2% of Agrify shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NRx Pharmaceuticals has higher earnings, but lower revenue than Agrify. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	111.24	-$28.62M	-$0.55	N/A
Agrify	$12.26M	3.83	-$41.75M	-$22.65	N/A

NRx Pharmaceuticals currently has a consensus target price of $34.50, suggesting a potential upside of 991.77%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe NRx Pharmaceuticals is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

NRx Pharmaceuticals beats Agrify on 9 of the 16 factors compared between the two stocks.

How does Agrify compare to Unicycive Therapeutics?

Agrify (NASDAQ:AGFY) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Agrify has a beta of 9.96, suggesting that its share price is 896% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Unicycive Therapeutics has a consensus price target of $18.75, indicating a potential upside of 289.81%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

6.0% of Agrify shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 2.2% of Agrify shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Unicycive Therapeutics had 12 more articles in the media than Agrify. MarketBeat recorded 13 mentions for Unicycive Therapeutics and 1 mentions for Agrify. Agrify's average media sentiment score of 0.67 beat Unicycive Therapeutics' score of 0.04 indicating that Agrify is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agrify	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Unicycive Therapeutics has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Unicycive Therapeutics' return on equity of -91.50% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Unicycive Therapeutics has lower revenue, but higher earnings than Agrify. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.83	-$41.75M	-$22.65	N/A
Unicycive Therapeutics	$680K	197.00	-$26.56M	-$1.75	N/A

Summary

Unicycive Therapeutics beats Agrify on 12 of the 16 factors compared between the two stocks.

Get Agrify News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGFY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGFY vs. The Competition

Export

Metric	Agrify	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$47.01M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-1.04	792.28	274.02	25.69
Price / Sales	3.83	860.21	632.76	76.07
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	2.24	10.62	10.44	6.32
Net Income	-$41.75M	$2.81B	$3.49B	$359.73M
7 Day Performance	12.43%	-0.08%	-0.66%	0.17%
1 Month Performance	3.16%	-1.31%	-3.16%	-3.27%
1 Year Performance	-37.98%	2.91%	15.15%	5.58%

Agrify Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGFY Agrify	N/A	$23.47 +0.8%	N/A	-40.4%	$47.01M	$12.26M	N/A	140	Gap Down
LFCR Lifecore Biomedical	1.0992 of 5 stars	$4.14 -2.6%	$6.50 +57.0%	-44.3%	$160.88M	$128.87M	N/A	382	Positive News Gap Down
MENS Jyong Biotech	N/A	$2.12 +1.9%	N/A	-96.5%	$158.14M	N/A	N/A	27	Gap Down
IMUX Immunic	2.3475 of 5 stars	$10.37 -7.7%	$47.25 +355.6%	+5.6%	$153.23M	N/A	N/A	95
NRXP NRx Pharmaceuticals	1.452 of 5 stars	$3.40 -2.6%	$34.50 +914.7%	+10.9%	$151.10M	$1.23M	N/A	29	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGFY) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agrify (AGFY) Competitors

AGFY vs. LFCR, MENS, IMUX, NRXP, and UNCY

How does Agrify compare to Lifecore Biomedical?

Summary

How does Agrify compare to Jyong Biotech?

Summary

How does Agrify compare to Immunic?

Summary

How does Agrify compare to NRx Pharmaceuticals?

Summary

How does Agrify compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGFY vs. The Competition

Agrify Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agrify (AGFY) Competitors

AGFY vs. LFCR, MENS, IMUX, NRXP, and UNCY

How does Agrify compare to Lifecore Biomedical?

Which has preferable earnings and valuation, LFCR or AGFY?

Is LFCR or AGFY more profitable?

Which has more volatility & risk, LFCR or AGFY?

Does the media favor LFCR or AGFY?

Do analysts recommend LFCR or AGFY?

Do insiders & institutionals believe in LFCR or AGFY?

Summary

How does Agrify compare to Jyong Biotech?

Does the media prefer AGFY or MENS?

Do insiders and institutionals hold more shares of AGFY or MENS?

Which has more volatility and risk, AGFY or MENS?

Do analysts prefer AGFY or MENS?

Which has preferable earnings and valuation, AGFY or MENS?

Is AGFY or MENS more profitable?

Summary

How does Agrify compare to Immunic?

Is AGFY or IMUX more profitable?

Does the media prefer AGFY or IMUX?

Which has stronger valuation and earnings, AGFY or IMUX?

Which has more risk & volatility, AGFY or IMUX?

Do insiders & institutionals hold more shares of AGFY or IMUX?

Do analysts prefer AGFY or IMUX?

Summary

How does Agrify compare to NRx Pharmaceuticals?

Which has more volatility and risk, NRXP or AGFY?

Is NRXP or AGFY more profitable?

Does the media favor NRXP or AGFY?

Do institutionals & insiders hold more shares of NRXP or AGFY?

Which has higher valuation & earnings, NRXP or AGFY?

Do analysts prefer NRXP or AGFY?

Summary

How does Agrify compare to Unicycive Therapeutics?

Which has more volatility and risk, AGFY or UNCY?

Do analysts rate AGFY or UNCY?

Do institutionals & insiders believe in AGFY or UNCY?

Does the media prefer AGFY or UNCY?

Is AGFY or UNCY more profitable?

Which has preferable earnings and valuation, AGFY or UNCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGFY vs. The Competition

Agrify Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools